Keeping a watchful eye on the food giants and cleansing the temple of nutritional medicine and epidemiology

Abstract

One of the most-loved enemies of medical editors, healthcare policy planners, scholars and scientists in the fields of medicine and public health is the companies that are known as "big pharma. " Indeed, our attitude is correct, because these companies keep on pushing products that lead to addiction to opioids and fentanyl (not unlike the addiction to heroin that is perpetrated by "traditional" drug dealers) 1 and indulge in disease-mongering such as highlighting testosterone insufficiency in males. 2-3 Two former editors of the New England Journal of Medicine, Marcia Angell and Jerome Kassirer, described in detail how "big pharma" works. Their reports did not receive any credible rebuttal from the pharmaceutical companies. 4-5 However, over the last two decades, the scientific community has been curbing the bad behavior of "big pharma. " Governments have demanded that medical associations should implement compliance policies regarding publicization and commercialization of pharmaceutical products during congresses and events. For talks and papers, disclosure of conflicts of interest by lecturers and authors has become the reality, and there is no chance of turning the clock back. The most Sources of funding: Recipient of a grant as an established researcher,